Drug Profile
Research programme: nicotine inhalation - Addicere Therapeutics
Alternative Names: Staccato-nicotineLatest Information Update: 08 Jan 2022
Price :
$50
*
At a glance
- Originator Addicere Therapeutics
- Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Smoking withdrawal
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Smoking-withdrawal in USA (Inhalation, Aerosol)
- 31 Dec 2013 Staccato® nicotine is no longer licensed to Cypress Bioscience worldwide (Alexza Pharmaceuticals Form 10-K for 2013)
- 12 Apr 2012 Preclinical trials in Smoking withdrawal in USA (Inhalation)